Multicenter prospective cohort study on the development of benign gallbladder disease and molecular analysis of bile composition in non-alcoholic fatty liver disease
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0005304
- Lead Sponsor
- Hanyang University Seoul Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 780
1. Patients hospitalized for cholecystectomy due to a benign disease of the gallbladder (gallstone or gallbladder polyp)
2. 19 to 80
1. For acute cholecystitis, grade II & III of Tokyo guideline 2018
2. In case of acute cholecystitis, hepatitis level is more than 5 times the upper limit of normal.
3. When jaundice level is more than 3 times the normal upper limit due to acute inflammation
4. If there is a tendency to hemorrhage due to prothrombin time less than 50,000 prolonged 1.5 times or more
5. In the past 2 years, alcoholic liver disease is suspected with a weekly alcohol consumption of 210g or more in men and 140g or more in women.
6. A case of liver disease caused by chronic hepatitis B or C
7. If you have a history of taking medications that can cause fatty liver
A. Glucocorticoid
B. Tamoxifen
C. Methotrexate
D. Valproate
E. Amiodarone
F. 5-fluorouracil
G. Irinotecan
H. Highly active antiretroviral therapy (HARRT)
8. If you have a genetic disease that causes fatty liver
A. Abetalipoproteinemia
B. Familial hypobetalipoproteinemia
C. Familial combined hyperlipidemia
D. Glycogen storage disease
E. Lipodystrophy
F. Weber-Christian disease
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biomarker
- Secondary Outcome Measures
Name Time Method Bile acid composition